Please assess the completion status of the following clinical trial:

Trial Title: Chitosan Dressings to Facilitate Safe Effective Debridement of Chronic Wounds & Minimize Wound Bacterial Re-colonization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years and are able to provide written informed consent.~* Have a wound on their body with an eschar and/or significant slough present~* Documented laboratory studies and coagulation profiles prior to the debridement (including hematocrit, hemoglobin, white blood count, total lymphocyte count, albumin, pre-albumin, HbA1C in patients with diabetes)~* Subjects with a hemoglobin \< 9 g/dL must have one unit of blood typed and cross matched prior to the debridement; all other subjects must have an active type and screen performed prior to the debridement procedure.~* Subjects must be willing to consent to a blood transfusion in the rare event that a transfusion is necessary.~* Must be expected to be inpatients for at least 5 days following debridement, to enable controlled dressing changes by the service.~* Female subjects of childbearing age must not be pregnant, and must consent to utilize an appropriate method of contraception during the course of the study.~For subjects that are to undergo a debridement in the operating room:~* Subjects must be sensate or have wounds that are sufficiently large to warrant a debridement in the OR~* Wounds must require more than a simple eschar removal, or must be extensive enough that an operating room debridement would be more appropriate.~* Subjects must be candidates for regional or general anesthesia, unless the wound occurs in an insensate body part (for example, a pressure sore in a paraplegic or quadriplegic patient, or a diabetic foot ulcer in a patient with a dense diabetic polyneuropathy).~For subjects that are to undergo a debridement in the bedside setting:~* The part of the wound that is to be debrided must be mostly an eschar and necrotic tissue which is not likely to have significant bleeding.~* Subjects must be insensate, or the wound must be less than 50 cm2 such that the use of local anesthesia in the wound can be undertaken.~Exclusion Criteria:~* Pre-debridement hemoglobin level \< 7.0 g/dL~* Not candidates for or refuse blood transfusions~* Unable to provide written informed consent~* Subjects with sensitivity to chitosan or the gauze dressings used in this study, or any local anesthetic needed for a debridement~* Subjects who are in the intensive care unit~* Subjects who, in the opinion of the Investigator, may not complete the study for any reason.~* Have grossly infected wounds that may reasonably be expected to require multiple debridement procedures prior to clearance of bacteria and nonviable tissue from the wound.~* For wounds situated in the lower extremity, leg must have either palpable pulses or else an ABI \> 0.4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HemCon Operating Room (Type: EXPERIMENTAL): The HemCon dressing is the intervention for the HemCon Operating Room arm. The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
- Control Operating Room (Type: ACTIVE_COMPARATOR): The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
- HemCon Bedside (Type: EXPERIMENTAL): The intervention for the HemCon Beside arm is the HemCon Dressing. The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
- Control Bedside. (Type: ACTIVE_COMPARATOR): The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.

Based on this trial design, predict the completion outcome and termination type (if applicable).